Abstract:Context Head and neck paragangliomas (HNPGLs) are rare, usually benign, slow‐growing tumours arising from neural crest‐derived tissue. Definitive management pathways for HNPGLs have yet to be clearly defined. Objective To review our experience of the clinical features and management of these tumours and to analyse outcomes of different treatment modalities. Methods Demographic and clinical data were obtained from The Northern Ireland Electronic Care Record (NIECR) as well from a prospectively maintained HNPGL database between January 2011 through December 2023. Results There were 87 patients; 50 females: 37 males with a mean age of 52.3 ± 14.2 years old (range 17–91 years old). 58.6% (n = 51) of patients had carotid body tumours, 25.2% (n = 22) glomus vagal tumours, 6.8% (n = 6) tumours in the middle ear, 2.2% (n = 2) in the parapharyngeal space and 1.1% (n = 1) in the sphenoid sinus. 5.7% (n = 5) of patients had multifocal disease. The mean tumour size at presentation was 3.2 ± 1.4 cm (range 0.5–6.9 cm). Pathogenic SDHD mutations were identified in 41.3% (n = 36), SDHB in 12.6% (n = 11), SDHC in 2.2% (n = 2) and SDHA in 1.1% (n = 1) of the patients. Overall treatment modalities included surgery alone in 51.7% (n = 45) of patients, radiotherapy in 14.9% (n = 13), observation in 28.7% (n = 25), and somatostatin analogue therapy with octreotide in 4.5% (n = 4) of patients. Factors associated with a significantly higher risk of recurrence included age over 60 years (p = .04), tumour size exceeding 2 cm (p = .03), positive SDHx variants (p = .01), and vagal and jugular tumours (p = .04). Conclusion The majority of our patients underwent initial surgical intervention and achieved disease stability. Our results suggest that carefully selected asymptomatic or medically unfit patients can be safely observed provided lifelong surveillance is maintained. We advocate for the establishment of a UK and Ireland national HNPGL registry, to delineate optimal management strategies for these rare tumours and improve long term outcomes.

Genetic and Clinical Characteristics of Head and Neck Paragangliomas in a Chinese Population

Non-Susceptibility Gene Variants in Head and Neck Paragangliomas

Algorithm of genetic diagnosis for patients with head and neck paraganglioma-update

Genetic Characteristics of Incidental Pheochromocytoma and Paraganglioma.

Adhesion molecule expression in vivo on extraocular muscles (EOM) in thyroid‐associated ophthalmopathy (TAO)

Genetic Predisposition to Pheochromocytoma and Paraganglioma: 21 Years' Experience in the Field

Succinate dehydrogenase mutations in head and neck paragangliomas: A systematic review and meta‐analysis of individual patients' data

Management and follow-up strategies for patients with head and neck paraganglioma

SDHA related phaeochromocytoma and paraganglioma: review and clinical management

Meralgia paresthetica in the parturient.

Novel and recurrent genetic variants of VHL, SDHB, and RET genes in Chinese pheochromocytoma and paraganglioma patients

SomaticIDH1Hotspot Variants in Chinese Patients with Pheochromocytomas and Paragangliomas

A new strategy to eliminate sample mixing during in-tube solid phase microextraction.

Medication use and kidney cancer risk: A population-based study.

Thyroid Paraganglioma: A Rare Manifestation of Paraganglioma Syndrome Associated With Pathogenic Variant in SDHD

SDHC Promoter Methylation, a Novel Pathogenic Mechanism in Parasympathetic Paragangliomas

[Study in rats of an experimental sprue syndrome].

Chromatin changes in frog neurons after eighth nerve transection.

Clinical management and outcome of head and neck paragangliomas (HNPGLs): A single centre retrospective study

Composite Pheochromocytoma/Paraganglioma-Ganglioneuroma: A Clinicopathologic Study of Eight Cases with Analysis of Succinate Dehydrogenase

Head and Neck Paraganglioma Atypically Carrying a Succinate Dehydrogenase Subunit B Mutation (L157X)